Bundle 3 (IC 2027)

Elyssa Zukin, MS, CGC is a licensed, board-certified genetic counselor specializing in cancer genetics at City of Hope National Medical Center. She has a Master of Science degree in genetic counseling from the University of California, Irvine, and a Bachelor of Science degree from the University of California, Los Angeles. Zukin joined City of Hope in 2020. Her role in the City of Hope Center for Precision Medicine involves the development and implementation of the return of germline genetic test results, and she has developed processes to improve the program’s efficiency and scalability. As part of the City of Hope Cancer Genomics Education Program, she is involved in the creation, implementation, and ongoing review of recorded learning modules, case-based exercises, and other learning materials. Her research has investigated the implications on clinical care when patients are found to carry genetic variants in genes associated with hereditary cancer syndromes that have conflicting interpretations by different genetics laboratories.

COLIN PRITCHARD, MD, PhD, is a Professor of Laboratory Medicine and Pathology at the University of Washington and Program Director for Cancer Precision Diagnostics for the Brotman Baty Institute for Precision Medicine. He also serves as the Co-Director of the Genetics and Solid Tumors Laboratory that services the Fred Hutchinson Cancer Center. The Pritchard laboratory focuses on oncology molecular diagnostics, particularly the source and utility of cell-free nucleic acid biomarkers in blood, and the development of innovative molecular diagnostics for the identification of DNA repair gene mutations that can guide therapeutic decision-making. His clinical work focuses on applications of next-generation sequencing gene panels for cancer risk assessment and precision treatment. He has led the development and implementation of the ColoSeq™ Lynch and Polyposis Syndrome Panel and the UW-OncoPlex™ Cancer Gene Panel in current clinical use for cancer patients and their families. He is a longstanding distinguished faculty member of the City of Hope Clinical Cancer Genomics Community of Practice. In 2021 Dr. Pritchard was awarded the C2 Catalyst for Precision Medicine Award from Scientific American.